Tumour immune cells could aid cancer therapies

A pioneering technique designed to spot differences between immune cells in tumours could speed the development of cancer treatments, research suggests. Scientists say the approach could be used to help doctors choose the best treatments for individual patients and predict which tumours are likely to respond to a particular therapy.

It could help target the use of immunotherapy - a new form of treatment that uses the body's own defences to tackle cancer. This therapy has shown great promise in recent years, but identifying which patients will respond best is a challenge for doctors.

The new approach - based on gene analysis - makes it easier to spot the range of immune cells present in a tumour. These cells could help the body detect and kill cancer when activated by certain drugs, scientists say.

Traditional treatments such as radiology do not discriminate between cell types and attack both cancerous and healthy cells, often leading to side-effects.

Researchers at the University of Edinburgh analysed genes from anonymised medical databases of thousands of tumours to identify genes associated with immune cells.

This allowed them to quickly detect immune cells in a tumour based on their genetic code even when they were mixed in with harmful cancerous cells and normal cells.

They say that this resource - called ImSig - paints the best picture of tumours to date and will allow scientists to study how certain immune cell types affect cancer growth.

In future, this could help doctors decide which patients were most likely to respond to immunotherapy, experts say.

The study is published in Cancer Immunology Research and was funded by the Biotechnology and Biological Sciences Research Council.

Professor Tom Freeman from the University of Edinburgh's Roslin Institute, who led the study, said: "Our approach, which helps us to find out exactly what cells make up a tumour is like deciphering which fruits went into making a smoothie. Although more work needs to be done before this could be used to help patients, we believe that this new technique is a step towards better understanding of tumours that could help guide patient treatment."

Ajit J Nirmal, Tim Regan, Barbara B Shih, David A Hume, Andrew H Sims, Tom C Freeman.
Immune Cell Gene Signatures for Profiling the Microenvironment of Solid Tumors.
Cancer Immunol Res November 2 2018 6 (11) 1388-1400. doi: 10.1158/2326-6066.CIR-18-0342.

Most Popular Now

Bayer Thrombosis Research Award 2019 goes to Dr. C…

The fourth winner of the Bayer Thrombosis Research Award has been chosen. The Scientific Committee of the Bayer Science & Education Foundation awarded the EUR 30,000 priz...

Roche enters into definitive merger agreement to a…

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) have entered into a definitive merger agreement for Roche to fully acquire Spark Therapeuti...

Brilinta’s Phase III THEMIS trial met primary endp…

The Phase III THEMIS trial met its primary endpoint and demonstrated that Brilinta (ticagrelor), taken in conjunction with aspirin, showed a statistically-significant red...

Protein content as a marker for response to therap…

Brain tumors vary widely in how they respond to treatment. However, early assessment of therapy response is essential in order to choose the best possible treatment for t...

Jury upholds Amgen's patents on Repatha® (evolocum…

Amgen (NASDAQ:AMGN) announced that a Delaware jury delivered a verdict in Amgen's favor upholding the validity of two Amgen patents related to PCSK9 antibodies. These pat...

Artificial lung cancer tissue could help find new …

A 3D hydrogel created by researchers in U of T Engineering Professor Molly Shoichet's lab is helping University of Ottawa researchers to quickly screen hundreds of potent...

Could medical marijuana help grandma and grandpa w…

Medical marijuana may bring relief to older people who have symptoms like pain, sleep disorders or anxiety due to chronic conditions including amyotrophic lateral scleros...

New treatment offers potentially promising results…

A pioneering clinical trials program that delivered an experimental treatment directly to the brain offers hope that it may be possible to restore the cells damaged in Pa...

Amgen, Cytokinetics and Servier announce start of …

Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecar...

Could blockchain ensure integrity of clinical tria…

UC San Francisco researchers have created a proof-of-concept method for ensuring the integrity of clinical trials data with blockchain. The system creates an immutable au...

Novartis data confirm rapid response and high effi…

Novartis announced today new data in 441 Chinese patients with moderate to severe plaque psoriasis from a Phase III study investigating the efficacy and safety of Cosenty...

Abbott and Novo Nordisk enter partnership to provi…

Abbott and Novo Nordisk today announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly...